We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+4.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.07B
AUM Growth
+$160M
(+2%)
Cap. Flow
-$9.78B
Cap. Flow
% of AUM
-121.29%
Top 10 Holdings %
Top 10 Hldgs %
33.87%
Holding
157
New
25
Increased
29
Reduced
33
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$192M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$173M |
| 3 |
Merck
MRK
|
+$94.1M |
| 4 |
Tenet Healthcare
THC
|
+$83.4M |
| 5 |
DaVita
DVA
|
+$79.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$9.91B |
| 2 |
Eli Lilly
LLY
|
+$193M |
| 3 |
Amgen
AMGN
|
+$156M |
| 4 |
Cigna
CI
|
+$151M |
| 5 |
Elevance Health
ELV
|
+$148M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.49% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $364M | 4.52% |
3,268,275
+388,700
| +13% | +$46.5M |
|
2
Regeneron Pharmaceuticals
REGN
$73.1B
| $332M | 4.11% |
962,900
+108,300
| +13% | +$37.7M |
|
3
Vertex Pharmaceuticals
VRTX
$125B
| $302M | 3.75% |
1,854,600
+113,300
| +7% | +$18.5M |
|
|
4
Merck
MRK
$324B
| $288M | 3.57% |
5,542,034
+1,742,615
| +46% | +$94.1M |
|
5
Biogen
BIIB
$32.1B
| $285M | 3.53% |
1,040,400
-190,300
| -15% | -$59.1M |
|
6
Boston Scientific
BSX
$68.4B
| $284M | 3.52% |
10,377,795
-8,805
| -0.1% | -$239K |
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $235M | 2.91% |
2,634,250
-428,600
| -14% | -$41.1M |
|
|
8
Bristol-Myers Squibb
BMY
$130B
| $232M | 2.88% |
3,675,300
+2,987,300
| +434% | +$192M |
|
9
Ascendis Pharma A/S
ASND
$16.8B
| $220M | 2.73% |
3,367,315
| – | – |
|
10
Agilent Technologies
A
$39.9B
| $190M | 2.35% |
2,836,900
+246,200
| +10% | +$17.3M |
|
11
Puma Biotechnology
PBYI
$405M
| $180M | 2.23% |
2,641,661
+457,126
| +21% | +$34.2M |
|
|
CMTA
12
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $158M | 1.96% |
10,425,225
| – | – |
|
13
Jazz Pharmaceuticals
JAZZ
$16.1B
| $157M | 1.95% |
1,040,100
+432,200
| +71% | +$63.4M |
|
|
ARMO
14
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
| $154M | 1.91% |
+4,118,903
| New | +$173M |
|
15
Alnylam Pharmaceuticals
ALNY
$38.5B
| $151M | 1.87% |
1,265,966
+324,366
| +34% | +$41.8M |
|
16
AbbVie
ABBV
$469B
| $145M | 1.79% |
1,527,500
+476,900
| +45% | +$52.4M |
|
17
Edwards Lifesciences
EW
$48.5B
| $143M | 1.77% |
3,073,800
-298,500
| -9% | -$13M |
|
|
WMGI
18
DELISTED
Wright Medical Group Inc
WMGI
| $136M | 1.69% |
6,852,068
| – | – |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $123M | 1.53% |
2,330,870
+359,200
| +18% | +$21M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $117M | 1.45% |
693,605
+406,315
| +141% | +$68.2M |
|
|
NVRO
21
DELISTED
NEVRO CORP.
NVRO
| $109M | 1.35% |
1,260,091
+362,300
| +40% | +$29.3M |
|
|
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
| $109M | 1.35% |
941,000
-93,159,036
| -99% | -$9.91B |
|
|
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
| $106M | 1.32% |
7,072,500
+1,500,000
| +27% | +$22.8M |
|
|
BOLD
24
DELISTED
Audentes Therapeutics, Inc
BOLD
| $106M | 1.31% |
3,522,100
-607,538
| -15% | -$20.6M |
|
|
25
DaVita
DVA
$15.6B
| $103M | 1.28% |
1,559,600
+1,082,200
| +227% | +$79.5M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q1 2018 Portfolio in Review
As of Q1 2018, OrbiMed held 157 positions worth $8.07B, up 2% from $7.91B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed withdrew a net $9.78B in Q1 2018, closing 16 positions and reducing 33 holdings. Its most notable exit was Eli Lilly, an estimated $193M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in ARMO BioSciences, Inc. Common Stock worth $154M.
- OrbiMed's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 4,118,903 shares worth $154M.
- OrbiMed added most to Bristol-Myers Squibb in Q1 2018, an estimated $192M increase.
- OrbiMed's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $9.91B.
- OrbiMed fully exited Eli Lilly in Q1 2018, selling an estimated $193M.
- OrbiMed's ten largest holdings make up 34% of its $8.07B portfolio in Q1 2018.
- OrbiMed opened 25 new positions and closed 16 in Q1 2018.
- OrbiMed's portfolio value rose 2% quarter-over-quarter to $8.07B.
Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.